India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
On 22nd July 2026, Honourable President Droupadi Murmu inaugurated a statue of the great Mahatma…
India has commissioned the INS Malvan, it is the second Mahe-class Anti-Submarine Warfare Shallow Water…
Samudra Pradakshina. is the first-ever circumnavigation expedition by women of all three Services of India.…
India has achieved a historic milestone in its railway modernization initiative with the electrification of…
Rahul Himalian, the Director (Tourism & Marketing), has been given the additional charge of the…
Tamil Nadu's the Killai village in Cuddalore being recognized as the first Climate-Resilient Village in…